Sugi Predict

Sugi Predict / Compounds / SCHEMBL1936057

SCHEMBL1936057

SCHEMBL1936057

Cc1cc(C)n(-c2nc(Cl)cc(Cl)n2)n1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.86
▸ ALOX15 P16050 4/20 0.54
▸ KMT2A Q03164 3/20 0.53
▸ NPSR1 Q6W5P4 3/20 0.53
▸ CYP1A2 P05177 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ CYP2C9 P11712 2/20 0.53
▸ CYP2C19 P33261 2/20 0.53
▸ LMNA P02545 1/20 0.53
▸ USP2 O75604 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ PTPN7 P35236 1/20 0.50
▸ CREBBP Q92793 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ BCL6 P41182 1/20 0.49
▸ NTSR1 P30989 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ XBP1 P17861 1/20 0.49
▸ MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11174391 0.92 HTT (1.00) HTTALOX15KMT2ANPSR1CYP1A2
SCHEMBL19687417 0.89 HTT (0.75) HTTALOX15KMT2ANPSR1CYP1A2
SCHEMBL2812766 0.88 HTT (0.73) HTTALOX15KMT2ANPSR1CYP1A2
SCHEMBL4138642 0.85 HTT (0.68) HTTALOX15KMT2ANPSR1CYP1A2
SCHEMBL21144202 0.84 HTT (0.68) HTTALOX15KMT2ANPSR1CYP1A2
SCHEMBL4140825 0.84 HTT (0.68) HTTALOX15KMT2ANPSR1CYP1A2
SCHEMBL19690985 0.84 HTT (0.67) HTTALOX15KMT2ANPSR1CYP1A2
SCHEMBL19691025 0.82 HTT (0.65) HTTALOX15KMT2ANPSR1CYP1A2
SCHEMBL11178856 0.82 HTT (0.65) HTTALOX15KMT2ANPSR1CYP1A2
SCHEMBL19691007 0.81 HTT (0.63) HTTALOX15KMT2ANPSR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 — — US disclosed
CN-110198935-B Potassium channel modulators 卡登特治疗公司 2022-05-31 — — CN disclosed
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-09 — — US disclosed
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-09 — — US disclosed
EP-3571193-B1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-01 — — EP disclosed
EP-3571193-B1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-01 — — EP disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 — — US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 — — US disclosed
US-10717728-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-07-21 — — US disclosed
US-10717728-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-07-21 — — US disclosed
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2017-12-14 — — US disclosed
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2017-12-14 — — US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 — — WO disclosed
US-8618099-B2 Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators ATAXION, INC. (US) 2013-12-31 — — US disclosed
US-20110230484-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2011-09-22 — — US disclosed
US-20110230484-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2011-09-22 — — US disclosed
US-20110230484-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2011-09-22 — — US disclosed
EP-2331527-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2011-06-15 — — EP disclosed
WO-2010026087-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-03-11 — — WO disclosed
WO-2010026087-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 HTT 1384/4885ALOX15 2894/4885KMT2A 1471/4885
US-20110230484-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNJ4, KCNN2 HTT 2022/4885ALOX15 3942/4885KMT2A 1586/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 HTT 1384/4885ALOX15 2894/4885KMT2A 1471/4885
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK10, KCNJ1 HTT 452/4885ALOX15 4375/4885KMT2A 817/4885
US-10717728-B2 Potassium channel modulators KCNJ2, KCNQ2, KCNJ1 HTT 788/4885ALOX15 2978/4885KMT2A 1059/4885
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 HTT 1113/4885ALOX15 2955/4885KMT2A 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.